EMA Withdrawn: Imatinib Teva B.V. (imatinib mesilate) — Teva B.V.

View source ↗

Summary

EMA withdrew the Imatinib Teva B.V. product (imatinib mesilate) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatofibrosarcoma
• Gastrointestinal Stromal Tumors
• Leukemia Myelogenous Chronic Bcr-abl Positive

Drugs mentioned

• Imatinib Teva B.V. (imatinib mesilate) (imatinib mesilate)

Snippet

Status: Withdrawn. Therapeutic area: Dermatofibrosarcoma;Gastrointestinal Stromal Tumors;Leukemia, Myelogenous, Chronic, BCR-ABL Positive. MAH: Teva B.V.. Decision date: 08/05/2018